Your browser is no longer supported. Please, upgrade your browser.
Settings
NERV Minerva Neurosciences, Inc. daily Stock Chart
NERV [NASD]
Minerva Neurosciences, Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own0.70% Shs Outstand39.24M Perf Week9.83%
Market Cap223.67M Forward P/E- EPS next Y-1.60 Insider Trans-65.34% Shs Float37.51M Perf Month39.36%
Income-55.50M PEG- EPS next Q-0.36 Inst Own73.20% Short Float7.57% Perf Quarter-15.93%
Sales- P/S- EPS this Y-19.90% Inst Trans-2.11% Short Ratio7.97 Perf Half Y6.15%
Book/sh1.42 P/B4.01 EPS next Y-10.30% ROA-44.40% Target Price19.20 Perf Year-32.14%
Cash/sh1.53 P/C3.73 EPS next 5Y- ROE-76.40% 52W Range4.01 - 9.12 Perf YTD-15.43%
Dividend- P/FCF- EPS past 5Y-48.60% ROI- 52W High-37.50% Beta1.48
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low42.14% ATR0.29
Employees13 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)57.10 Volatility6.91% 6.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-15.40% Profit Margin- Rel Volume0.51 Prev Close5.72
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume356.36K Price5.70
Recom1.60 SMA2015.98% SMA501.18% SMA200-12.72% Volume219,985 Change-0.35%
Oct-02-19Reiterated Chardan Capital Markets Buy $17
Sep-25-19Initiated Chardan Capital Markets Buy $17
Sep-18-19Initiated William Blair Outperform
May-31-19Initiated H.C. Wainwright Buy
Sep-01-17Initiated Citigroup Buy $11
Mar-06-17Resumed Jefferies Buy $17
May-12-16Resumed Jefferies Buy
Nov-21-19 12:21AM  Edited Transcript of NERV earnings conference call or presentation 4-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-14-19 08:30AM  Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019 GlobeNewswire
Nov-11-19 12:10AM  Minerva Neurosciences, Inc (NERV): Are Hedge Funds Right About This Stock? Insider Monkey
Nov-04-19 07:30AM  Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates GlobeNewswire
Oct-28-19 08:30AM  Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019 GlobeNewswire
Oct-18-19 09:37AM  Does The Minerva Neurosciences, Inc. (NASDAQ:NERV) Share Price Tend To Follow The Market? Simply Wall St.
Oct-02-19 08:47AM  Company News For Oct 2, 2019 Zacks -12.96%
Oct-01-19 04:43PM  Investor Alert: Kaplan Fox Investigates Minerva Neurosciences, Inc. (NASDAQ: NERV) PR Newswire -26.32%
09:23AM  Stocks - U.S. Steel Slumps, Spotify, Tesla Rise Premarket Investing.com
08:49AM  Minerva's stock plunges to lead all premarket losers after cyber-attack delays enrollment in a phase 3 trial MarketWatch
07:30AM  Minerva Neurosciences Announces Update for Three Clinical Trials GlobeNewswire
Sep-26-19 04:10PM  Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET GlobeNewswire
Sep-24-19 09:00AM  Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone GlobeNewswire
Sep-23-19 11:46AM  Zacks.com featured highlights include: ACM Research, GAIN Capital, Cutera, Columbus McKinnon and Minerva Zacks
Sep-20-19 09:10AM  Moving Average Crossover Alert: Minerva Neurosciences Zacks
Sep-19-19 09:38AM  5 Stocks to Buy on New Analyst Coverage Zacks
Sep-03-19 10:53AM  What Kind Of Shareholder Appears On The Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Shareholder Register? Simply Wall St.
Aug-09-19 03:08AM  Edited Transcript of NERV earnings conference call or presentation 5-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-05-19 03:59PM  Minerva Neurosciences, Inc. (NERV) Q2 2019 Earnings Call Transcript Motley Fool +8.06%
07:30AM  Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates GlobeNewswire
Jul-29-19 08:00AM  Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019 GlobeNewswire
Jul-04-19 11:36AM  Did Minerva Neurosciences, Inc. (NASDAQ:NERV) Insiders Buy Up More Shares? Simply Wall St.
Jun-28-19 03:19PM  Is Minerva Neurosciences, Inc (NERV) A Good Stock To Buy? Insider Monkey
Jun-24-19 11:00AM  Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial Benzinga +40.19%
08:12AM  UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals MarketWatch
07:30AM  Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia GlobeNewswire
Jun-23-19 05:30PM  Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant GlobeNewswire
Jun-12-19 08:30AM  Minerva Neurosciences to Present at JMP Securities Life Sciences Conference GlobeNewswire
May-29-19 08:30AM  Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019 GlobeNewswire
May-13-19 11:01AM  Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug Benzinga
08:15AM  Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs GlobeNewswire
May-10-19 09:29AM  Edited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-07-19 02:06PM  Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Simply Wall St.
May-06-19 12:00PM  Minerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call Transcript Motley Fool -5.15%
07:35AM  Minerva Neurosciences: 1Q Earnings Snapshot Associated Press
07:30AM  Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates GlobeNewswire
Apr-29-19 08:30AM  Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019 GlobeNewswire
Apr-11-19 08:30AM  Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia GlobeNewswire
Mar-18-19 11:41AM  Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
08:30AM  Minerva Neurosciences to Host Webcast Event on Schizophrenia GlobeNewswire
Mar-12-19 12:53PM  Minerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:46AM  Minerva Neurosciences: 4Q Earnings Snapshot Associated Press
07:30AM  Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates GlobeNewswire
Mar-05-19 08:00AM  Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019 GlobeNewswire
Feb-05-19 08:30AM  Factors of Influence in 2019, Key Indicators and Opportunity within Wright Medical Group N.V, MSA Safety Incorporporated, Minerva Neurosciences, OSI, Argan, and Approach Resources New Research Emphasizes Economic Growth GlobeNewswire
Dec-20-18 11:32AM  How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own? Simply Wall St.
Nov-28-18 08:00AM  Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain GlobeNewswire
Nov-21-18 08:30AM  Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018 GlobeNewswire
Nov-19-18 08:00AM  Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers GlobeNewswire
Nov-16-18 04:49AM  Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-15-18 08:30AM  Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018 GlobeNewswire
Nov-09-18 08:10AM  New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -6.46%
Nov-07-18 08:30AM  Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018 GlobeNewswire +5.66%
Nov-05-18 11:10AM  Edited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMT Thomson Reuters StreetEvents -9.74%
07:47AM  Minerva Neurosciences: 3Q Earnings Snapshot Associated Press
07:30AM  Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates GlobeNewswire
Oct-29-18 08:30AM  Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018 GlobeNewswire
Oct-16-18 08:10AM  Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +7.88%
Oct-10-18 01:17PM  Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying Simply Wall St.
Sep-05-18 06:07PM  J&J Submits NDA to the FDA for Depression Drug in Adults Zacks
Aug-23-18 08:23AM  The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero Benzinga
Aug-22-18 08:30AM  Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF) GlobeNewswire +8.38%
Aug-16-18 07:50AM  New Research Coverage Highlights EMCORE, Earthstone Energy, Pareteum, Lydall, Minerva Neurosciences, and Drive Shack Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-04-18 05:19AM  Edited Transcript of NERV earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 10:12AM  Minerva Neurosciences: 2Q Earnings Snapshot Associated Press
07:30AM  Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates GlobeNewswire
Jul-26-18 08:31AM  Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018 GlobeNewswire
Jul-25-18 08:01AM  Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel GlobeNewswire
Jul-17-18 04:06PM  Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors GlobeNewswire
May-30-18 08:31AM  Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018 GlobeNewswire
08:30AM  Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018 GlobeNewswire
May-22-18 07:35AM  Recent Analysis Shows Capital Senior Living, Digital Realty Trust, Minerva Neurosciences, Zix, First Merchants, and PennantPark Investment Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
May-17-18 08:21AM  Minerva Neurosciences shares rise 5% on trial results for schizophrenia drug MarketWatch +13.85%
08:01AM  Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp... GlobeNewswire
08:00AM  Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia GlobeNewswire
May-09-18 01:46PM  Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-03-18 10:09AM  Minerva Neurosciences: 1Q Earnings Snapshot Associated Press -9.56%
07:31AM  Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates GlobeNewswire
Apr-26-18 08:31AM  Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018 GlobeNewswire
08:30AM  Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018 GlobeNewswire
Apr-09-18 08:31AM  Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder GlobeNewswire
08:30AM  Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder GlobeNewswire
Mar-28-18 08:30AM  Detailed Research: Economic Perspectives on Altisource Residential, Sykes Enterprises, Gibraltar Industries, Silicon Laboratories, TC PipeLines, LP, and Minerva Neurosciences What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-23-18 11:04AM  Will Minerva Neurosciences (NERV) Continue to Surge Higher? Zacks
Mar-15-18 08:31AM  Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22 GlobeNewswire
Mar-12-18 09:11PM  Edited Transcript of NERV earnings conference call or presentation 12-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
07:53AM  Minerva Neurosciences posts 4Q profit Associated Press
07:31AM  Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates GlobeNewswire
07:30AM  Minerva Neurosciences Inc to Host Earnings Call ACCESSWIRE
Mar-05-18 08:31AM  Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018 GlobeNewswire
Feb-05-18 08:31AM  Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director GlobeNewswire -7.26%
08:30AM  Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director GlobeNewswire
Jan-25-18 07:30AM  New Research: Key Drivers of Growth for Sykes Enterprises, Minerals Technologies, Minerva Neurosciences, Gibraltar Industries, Berkshire Hills, and Cheniere Energy Partners LP Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-21-17 08:02AM  Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With... GlobeNewswire +7.76%
08:00AM  Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder GlobeNewswire
Dec-20-17 11:25AM  Minerva Initiates Phase III Study on Schizophrenia Candidate Zacks
Dec-19-17 08:01AM  Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia GlobeNewswire
08:00AM  Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia GlobeNewswire
Dec-11-17 04:44PM  Minerva Neurosciences Names Richard Russell President GlobeNewswire +6.14%
08:17AM  Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors GlobeNewswire
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, NV for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOYLE WILLIAM FDirectorJun 27Buy5.503,50019,25026,111Jul 01 04:43 PM
VAN HEEK G JANDirectorJun 26Buy5.3710,00053,70013,333Jun 27 04:30 PM
HILLEMAN JERYL LDirectorJun 26Buy5.251,0005,2501,000Jun 27 04:28 PM
HASLER HANS PETERDirectorJun 26Buy5.6010,00056,00010,000Jun 27 04:28 PM
Kupfer DavidDirectorJun 26Buy5.5510,00055,500219,188Jun 27 04:26 PM
Index Venture Associates III L10% OwnerJun 24Sale6.01197,0001,184,8373,899,189Jun 26 04:12 PM
Index Venture Associates III L10% OwnerJun 20Sale4.3433,575145,7594,096,189Jun 21 04:12 PM
Index Venture Associates III L10% OwnerJun 19Sale4.4477,243343,1524,129,764Jun 21 04:12 PM
Index Venture Associates III L10% OwnerJun 18Sale4.4449,675220,5224,207,007Jun 19 04:10 PM
Index Venture Associates III L10% OwnerJun 17Sale4.4556,243250,2084,256,682Jun 19 04:10 PM
Index Venture Associates III L10% OwnerJun 14Sale4.5025,169113,1884,312,925Jun 17 04:26 PM
Index Venture Associates III L10% OwnerJun 13Sale4.5153,298240,5504,338,094Jun 17 04:26 PM
Index Venture Associates III L10% OwnerJun 12Sale4.5726,901122,9894,391,392Jun 13 04:55 PM
Index Venture Associates III L10% OwnerJun 11Sale4.7833,150158,3544,418,293Jun 13 04:55 PM
Index Venture Associates III L10% OwnerMay 20Sale6.082001,2154,451,443May 21 04:10 PM
Index Venture Associates III L10% OwnerMay 17Sale6.0222,718136,6814,451,643May 21 04:10 PM
Index Venture Associates III L10% OwnerMay 16Sale6.3744,836285,6734,474,361May 16 06:09 PM
Index Venture Associates III L10% OwnerMay 15Sale6.6453,418354,4664,519,197May 16 06:09 PM
Index Venture Associates III L10% OwnerMay 14Sale7.0536,574258,0224,572,615May 16 06:09 PM
DOYLE WILLIAM FDirectorDec 20Buy6.502,00013,00022,611Dec 26 04:43 PM
Race GeoffEVP, CFO & CBODec 17Sale7.465,99944,753198,370Dec 18 04:30 PM
Ahlholm Frederick WSVP, Chief Accounting OfficerDec 17Sale7.461,55911,63011,780Dec 18 04:29 PM
Luthringer RemyCEODec 17Sale7.462,60419,42632,702Dec 18 04:28 PM
Reilly Joseph H.SVP & Chief Operating OfficerDec 17Sale7.462,72820,35120,199Dec 18 04:27 PM
Russell Richard E.PresidentDec 12Sale7.963,11724,81136,883Dec 13 04:43 PM
DOYLE WILLIAM FDirectorDec 11Buy7.954,00031,80020,611Dec 12 05:18 PM
DOYLE WILLIAM FDirectorDec 10Buy8.002,00016,00016,611Dec 12 05:18 PM